Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Amyloid Cardiomyopathy: Specificities of Transthyretin V30 Mutation compared to Wild Type forms
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 06 – EXPLORANDO A AMILOIDOSE CARDÍACA: INOVAÇÕES NO DIAGNÓSTICO, PROGNÓSTICO E TRATAMENTO
Speaker:
Mariana Pereira Fernandes dos Santos
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.6 Myocardial Disease – Clinical
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Mariana Pereira Santos; Alexandra Pinto Pires; David Sá Couto; Diana Ribeiro; Pedro Monteiro; Tiago Peixoto; Andreia Campinas; Marta Fontes Oliveira; Sara Fernandes; Hipólito Reis; Severo Torres; Patrícia Rodrigues
Abstract
<p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Background:</strong> Transthyretin amyloidosis (ATTR) results from mutations in the TTR gene (vATTR) or conformational changes in wild-type protein (wtATTR). Regarding TTR mutations, the Familial Amyloid Polyneuropathy phenotype is endemic in Portugal, with the V30M being the most common pathogenic variant. Our goal is to characterize cardiac manifestations of V30M ATTR patients, particularly amyloid cardiomyopathy (CM). </span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Methods:</strong> We conducted a retrospective study including patients with TTR V30M mutation, with and without CM, consecutively observed at our center in Cardiology appointments in 2019 and followed for at least 5 years. Diagnostic criteria for ATTR-CM were considered according to ESC recommendations. Data on severe aortic stenosis, atrial fibrillation (Afib) and conduction abnormalities, were also collected. “Significant conduction disease” was considered in patients with a clear recommendation for pacemaker implantation or in those whose initial indication was uncertain but who eventually required more than 10% pacing. V30M ATTR-CM patients were compared to a cohort with wtATTR-CM.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Results: </strong>We enrolled a total of 248 TTR V30M patients, with a mean age of 54 years old, mostly male (53%) and with early onset disease (<50 years) (68%). 49 (21%) patients fulfilled the criteria for ATTR-CM diagnosis.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt">Significant electric conduction diseases were present in 31% of patients and were notably higher within the CM group (57% vs 25%, p<0.001). Overall, among pacemaker carriers, only 61% (n=77) had a significant conduction disease. Afib was noted in 11% of the entire cohort, being significantly more frequent among patients with CM (31% vs 6%, p<0.001). Severe aortic stenosis was rare, present in only 4 patients of the entire cohort.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt">In comparison with a cohort of patients with wtATTR-CM (n=44), patients with V30M vATTR-CM were significantly younger and had more electric conduction abnormalities and orthostatic hypotension. On the other hand, AFib, systolic dysfunction and hypertension were less frequent, which parallelled with lower levels of NT-proBNP and troponin T (Table 1).</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Conclusion</strong>: Our findings highlight the need for thorough cardiovascular evaluation in TTR V30M patients due to frequent conduction disease and CM. V30M ATTR-CM patients are younger, have more conduction abnormalities, and a lower prevalence of AFib compared to those with wtATTR-CM. Further prospective studies are needed to explore differences in CM between variant and wild-type cases.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site